Atopic Dermatitis (AD) Market
DelveInsight’s ‘Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the United States.
The Atopic Dermatitis (AD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted United States Atopic Dermatitis (AD) market size from 2018 to 2030. The report also covers current Atopic Dermatitis (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
- The United States
Study Period: 2018–2030
Atopic Dermatitis (AD) Disease Understanding and Treatment Algorithm
Atopic Dermatitis (AD) Overview
Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.
AD presents different symptoms depending on the age of the person. Itching is the hallmark of AD; more than 85% of people with the condition experience this distressing symptom every day. The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from compromised skin barrier leading to drier skin that is more prone to water loss and the entry of irritants. Thus, AD is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and environmental factors that disrupt the epidermis causing intensely pruritic skin lesions.
There is currently no reliable biomarker that can distinguish the disease from other entities. However, the most commonly used biomarker is elevated total and/or allergen-specific serum IgE. Occasionally, patients carrying an AD diagnosis may display atypical clinical features, chronic dermatoses, infectious processes, and primary immunodeficiency may mimic the presentation leading to the differential diagnosis. Noninfectious dermatoses include contact dermatitis, seborrheic dermatitis, and psoriasis.
Atopic Dermatitis (AD) Diagnosis
At present, there is no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.
Atopic Dermatitis (AD) Treatment
Significant psychological, social, and emotional impact is experienced by people with the condition daily. In addition to the visual and physical issues, AD can have a significant impact on the quality of life (QoL) of people. Currently, there is no cure for AD; however, it can be effectively managed with current treatment options. The pattern of the disease and its severity determine the kind of treatment the patient ought to receive.
The current US market for AD is dominated by topical treatment options such as emollients, topical corticosteroids (TCS) + antibiotics, topical calcineurin inhibitors (TCIs), and systemic treatment such as immunosuppressant, corticosteroids, Dupixent (Dupilumab), and others (phototherapy). Drugs such as Olumiant (Baricitinib) are approved in Europe only, whereas Corectim Ointment 0.5% is approved in Japan and Eucrisa (Crisaborole) 2% ointment in both US and Europe. The maintenance therapy for AD consists of the liberal use of emollients and daily bathing practice with soap-free cleansers. The use of TCS is the first-line treatment for AD flare-ups. Pimecrolimus and Tacrolimus are TCIs that can be used in conjunction with TCS. Ultraviolet phototherapy is a safe and effective treatment for moderate-to-severe AD when first-line treatments are not adequate. In addition to these, antistaphylococcal antibiotics are effective in treating secondary skin infections. Patients with severe sleep disturbance due to pruritus are offered a short-term, intermittent course of an oral sedating antihistamine such as diphenhydramine (Benadryl) or hydroxyzine; however, they are not routinely recommended because of lack of evidence that they reduce pruritus and the risk of development of contact dermatitis.
Atopic Dermatitis (AD) Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Atopic Dermatitis, Diagnosed Prevalent Population of Atopic Dermatitis, Severity-specific Distribution of Atopic Dermatitis in Adults, Severity-specific Distribution of Atopic Dermatitis in Pediatric Population and Gender-specific Distribution of Atopic Dermatitis in Adults in the United States market from 2018 to 2030.
This section provides glimpse of the AD epidemiology in the United States.
- The total prevalent population of AD in the United States was estimated to be 32,197,083 in 2020.
- The total diagnosed prevalent population of AD in the United States was estimated to be 25,091,967 in 2020.
- The prevalent population of AD in the United States is expected to increase at a CAGR of 0.58% during the study period 2018–2030.
- In the United States, the total number of adult cases of AD comprised of 5,684,566 males and 9,421,907 females in 2020.
- The total number of cases of mild AD were 9,065,394 in the United States, in 2020, as compared to the cases of moderate and severe AD with 4,365,771 and 1,661,712 cases respectively, in adults.
- In children, the total number of cases of mild AD were 6,690,281, in 2020, as compared to the cases of moderate and severe AD with 2,596,228 and 698,985 cases respectively, in the United States.
The United States - Atopic Dermatitis (AD) Epidemiology
The epidemiology segment also provides the Atopic Dermatitis (AD) epidemiology data and findings across the United States.
Atopic Dermatitis (AD) Drug Chapters
The drug chapter segment of the Atopic Dermatitis (AD) report encloses the detailed analysis of Atopic Dermatitis (AD) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Atopic Dermatitis (AD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Atopic Dermatitis (AD) Marketed Drugs
Eucrisa/Staquis (Crisaborole): Pfizer
Eucrisa (crisaborole) is a non-steroidal phosphodiesterase-4 (PDE4) inhibitor indicated for the topical treatment of mild-to-moderate AD in patients 2 years of age and older. It is currently available as a 2% ointment. The drug is a small, boron-based molecule with low molecular weight, which allows easier penetration into the skin. It is important to note that the drug is approved under the name, Staquis, in Europe to treat adults and children from 2 years of age with mild-to-moderate AD and is used when dermatitis affects up to 40% of the body’s surface. In March 2020, the US FDA approved Pfizer’s supplemental new drug application (sNDA) for Eucrisa (crisaborole) ointment, 2%, extending the lower age limit from 24 months down to 3 months in children with mild-to-moderate AD, also known as eczema. However, it was previously approved by the brand name Eucrisa for use in adults and children 2 years of age and older. This supplemental approval made Eucrisa the first and only steroid-free topical prescription medication for mild-to-moderate AD patients as young as 3 months of age.
Product details in the report…
Dupixent (dupilumab): Regeneron Pharmaceuticals
Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins and is not an immunosuppressant. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in AD, asthma, and chronic rhinosinusitis with nasal polyposis. Dupixent is currently approved in more than 60 countries, and more than 190,000 patients have been treated globally. However, the drug is not yet approved for treating AD patients below 6 years of age and is currently in Phase III clinical developmental trial for participants ≥6 months to <18 years of age with AD in collaboration with Sanofi.
Product details in the report…
Atopic Dermatitis (AD) Emerging Drugs
Rinvoq (upadacitinib): AbbVie
Upadacitinib (ABT-494) – discovered and developed by AbbVie scientists and marketed as Rinvoq – is a selective and reversible JAK inhibitor that was approved by FDA and EMA in August 2019 and December 2019, respectively, for adult patients with moderately to severely active rheumatoid arthritis. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. In October 2020, AbbVie submitted an application to the FDA and EMA seeking approval for Rinvoq for the treatment of adults (15 mg and 30 mg, once daily) and adolescents (15 mg, once daily) with moderate-to-severe AD. The drug received Breakthrough Therapy designation in 2018.
Product details in the report…
B244: AOBiome Therapeutics
AOBiome’s B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. The drug is currently undergoing a phase II trial pruritus (itch) caused by AD (eczema) in adults ages 18–65 years in various locations.
Product details in the report…
Ly3650150: Eli Lilly and Company
Lebrikizumab (Ly3650150, Drm06), a novel, investigational, monoclonal antibody, is designed to bind IL-13 with very high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology underlying the range of signs and symptoms of AD by promoting type II inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening, and infection. The US FDA has granted Fast Track designation to lebrikizumab for moderate-to-severe AD in patients aged 12 years and older and 40 kg or greater. The drug is being evaluated in five Phase III studies, ADvocate1 and ADvocate2 monotherapy studies and ADhere study in combination with topical corticosteroids to confirm its safety and efficacy in adolescent and adult patients, ages 12 years and older and 40 kg or greater, with moderate-to-severe AD, along with the ADore adolescent open-label safety study and ADjoin long term extension study.
Product details in the report…
Etrasimod: Arena Pharmaceuticals
Etrasimod (APD334) is a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena and designed for optimized pharmacology and engagement of S1P receptor 1, 4, and 5 providing systemic and local effects on specific immune cell types. The drug has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn’s disease, AD, and alopecia areata. In November 2020, based on the compelling profile in the ADVICE trial, the company mentioned that the drug would be proceeding further into a Phase III registrational program.
Product details in the report…
Abrocitinib (PF-04965842) is an oral, small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 modulates multiple cytokines involved in the pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP). The drug received Breakthrough Therapy designation from the FDA to treat patients with moderate-to-severe AD in February 2018. In October 2020 the FDA, accepted the filing of the company’s NDA for abrocitinib (100 mg and 200 mg) and granted Priority Review designation; the decision is anticipated in April 2021. The drug also received a promising innovative medicine (PIM) designation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in 2020, which indicated that the product might be eligible for the early access to medicines scheme (EAMS) based on early clinical data.
Product details in the report…
FB-401: Forte Biosciences
FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal R. mucosa for the treatment of inflammatory skin disease developed in collaboration with the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 consists of three therapeutic strains of a commensal gram-negative bacteria, Roseomonas mucosa that was specifically selected for their impact on key parameters of inflammatory skin disease. The drug received FDA Fast track designation in 2020. The company is currently enrolling participants in Phase II trial for FB-401 with 2 years of age and older AD patients.
Product details in the report…
FB825: Oneness Biotech
FB825 is a humanized monoclonal antibody that binds to the CεmX domain of membrane form IgE, leading to the death of IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC). The drug has both therapeutic as well as preventive effects in allergic diseases. In April 2020, LEO Pharma signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan) covering the development and commercialization of the novel AD drug candidate, FB825. The company is expecting to publish the complete results of this Phase II trial in 2021.
Product details in the report…
Atopic Dermatitis (AD) Market Outlook
The treatment of AD aims to reduce the duration, severity, and frequency of disease exacerbations (flares). It is implemented in a step-wise manner according to disease severity (mild, moderate, or severe).
Off-label treatment, especially systemic immunosuppressants and systemic (oral and injectable) corticosteroids (SCSs) are frequently prescribed for patients unresponsive to topical therapy. Systemic corticosteroids (SCS) are indicated for short-term treatment of acute severe AD. Although SCS rapidly improves symptoms, they are not recommended for long-term use because of the adverse events.
Optimal AD management includes topical corticosteroids (TCs) as the first-line treatment for AD flare-ups. The potencies of these topical corticosteroids range from the group I, which is most potent (e.g., clobetasol [Temovate]), through group VII, which is least potent (e.g., hydrocortisone 1%). However, TCS has various side-effects and is not recommended for long-term use. The principal complication of prolonged application of topical corticosteroids, especially those of higher-potency, is skin atrophy. Other local complications include telangiectasia, striae, hypopigmentation, and corticosteroid acne.
Topical calcineurin inhibitors, such as pimecrolimus (Elidel) and tacrolimus (Protopic), are immunomodulators and are considered second-line therapy. They are generally reserved for short-term or intermittent long-term therapy in persons with moderate-to-severe AD, especially when there is concern that the ongoing use of topical corticosteroids is causing adverse effects, such as atrophy.
Two topical calcineurin inhibitors (TCIs), pimecrolimus 1% cream (Elidel) and tacrolimus 0.03% ointment (Protopic), which selectively inhibit the synthesis of inflammatory cytokines released from T-cells and mast cells, have been available as second-line therapy since 2000–2001, for the short-term and non-continuous chronic treatment of mild-to-moderate AD in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.
Besides the above-mentioned off-label therapies, the treatment regimen of AD also involves certain approved and marketed therapies. Pfizer’s Eucrisa/Staquis (crisaborole, 2%) is a non-steroidal, phosphodiesterase-4 (PDE4) inhibitor that is approved for the topical treatment of mild-to-moderate AD in patients 2 years of age and older. It was approved in the EU in March 2020 (by the brand name Staquis) and the US in December 2016, with a label expansion in March 2020, extending the lower age limit from 24 months down to 3 months in children, which makes it the only medication for such young population. Currently, the drug is not approved in Japan; however, it has completed Phase III developmental clinical trial in Japanese pediatric and adult participants with mild-to-moderate AD.
In October 2020, Olumiant (baricitinib), an oral selective Janus kinase (JAK) 1/JAK2 inhibitor, received approval in the European Union for the treatment of adult patients with moderate-to-severe AD who are candidates for systemic therapy. It is the first oral JAK inhibitor to treat moderate-to-severe AD in adult patients who are candidates for systemic therapy in the EU and offers a different mode of action to the currently available treatment options. It is not yet approved by the FDA to treat AD; however, it is approved to treat rheumatoid arthritis (RA) in the US and over 60 countries. Additionally, Eli Lilly and partner Incyte have filed a regulatory review for Olumiant to treat AD in the US and Japan with Eli Lily Nederland as the marketing authorization holder.
The emerging pipeline of AD is quite robust, with various promising lead candidates in the late- and mid-stages of development, which is yet to be launched. The potential candidates with promising results in the late- or phase III stage of clinical development include RINVOQ/ upadacitinib (ABT-494) (AbbVie), lebrikizumab/LY3650150 (Eli Lilly and Company), abrocitinib/PF-04965842 (Pfizer), nemolizumab/CD14152 (Galderma), tralokinumab ± topical corticosteroids (LEO Pharma), difamilast/OPA-15406 (Otsuka Pharmaceutical), ARQ-151/roflumilast cream (Arcutis Biotherapeutics), and ruxolitinib cream (Incyte).
This section includes a glimpse of the Atopic Dermatitis (AD) United States market.
- The market size of AD in the United States was estimated to be USD 10,353 Million in 2020, which is expected to show a positive growth at a CAGR of 9.86% during the study period 2018–2030.
- The market size of emerging therpaies of AD in the United States is estimated to be USD 117 Million in 2021.
The United States Market Outlook
This section provides the total Atopic Dermatitis (AD) market size and market size by therapies in the United States.
Atopic Dermatitis (AD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Atopic Dermatitis (AD) market or expected to get launched in the market during the study period 2018–2030. The analysis covers Atopic Dermatitis (AD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Atopic Dermatitis (AD) Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Atopic Dermatitis (AD) emerging therapies.
Competitive Intelligence Analysis
We perform competitive and market intelligence analysis of the Atopic Dermatitis (AD) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Atopic Dermatitis (AD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
- Comprehensive insight has been provided into the Atopic Dermatitis (AD) epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Atopic Dermatitis (AD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of Atopic Dermatitis (AD) market; historical and forecasted is included in the report, covering the United States drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States Atopic Dermatitis (AD) market.
- In the coming years, Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis (AD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Delvelnsight has analysed the total prevalent and total diagnosed prevalent population of Atopic Dermatitis (AD).
- Delvelnsight has analysed gender-specific distribution of AD. As per the analysis, AD is more prevalent in females than in males.
- In addition, severity-specific data of AD in children and adults were also analyzed, according to which the population of AD can be categorized as mild, moderate and severe AD. As per the DelveInsight’s estimates, it has been found that the mild form of AD included maximum cases, while minimum number of cases were found in severe form of AD in both populations. This trend is clearly evident in the United States for the study period 2018–2030.
- Currently, the treatment regimen of AD involves the use of topical treatment options such as emollients, topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), Crisaborole (2%) ointment and systemic treatment such as immunosuppressant, corticosteroids, Dupixent and others (phototherapy).
- Expected Launch of potential mid and late-stage therapies, Rinvoq, Lebrikizumab, Etrasimod, FB825, Nemolizumab, Tralokinumab ± TCS, DS107, Bermekimab, KY1005, Q301, Ruxolitinib cream, Abrocitinib, FB-401, Roflumilast and Difamilast may increase the market size in the coming years. Additionally, the approved therapy, Dupixent is currently being developed for the pediatric population as well while Olumiant, which is already approved in Europe, is currently being investigated for 2 Years to 17 Years patients with AD.
- AD market has considerable growth opportunity across all severities and age groups. Even though several oral JAK inhibitors are expected to enter the market soon, it is highly unlikely that Dupixent will be replaced as the first-line treatment of AD for the foreseeable future due to its known safety profile.
- Eli Lilly believes that AD has a significant growth opportunity with significant unmet needs where Olumiant can play a crucial role. The company has already launched the drug outside of the US and are hopeful to have approval in the US in the first half of 2021. The company has taken safety quite seriously, apparent by the release of readouts and the broad set of data in the post-marketing of Olumiant. In addition, it has published quite a bit of data, over 8 years, at the end of last year concerning Olumiant’s effect on rheumatoid arthritis (RA) and has not raised any new safety signals. Thus, it feels confident and optimistic about Olumiant’s benefit-risk profile.
- The data readouts for Rinvoq demonstrated a distinct efficacy edge for Rinvoq over Dupixent, abrocitinib, Olumiant, and tralokinumab (anti-IL-13). However, the Heads Up trial, in particular, included some safety concerns for Rinvoq, with one patient death due to bronchopneumonia associated with influenza A and a higher rate of serious infections for the drug arm than the Dupixent arm (1.1% vs. 0.6%) as well as an imbalance in SAEs (2.9% vs 1.2%). We believe that initial Rinvoq adoption in AD is likely to be limited to Dupixent-inadequate responders largely on class safety concerns and Dupixent’s near-pristine safety profile.
Atopic Dermatitis (AD) Report Insights
- Patient Population
- Therapeutic Approaches
- Atopic Dermatitis (AD) Pipeline Analysis
- Atopic Dermatitis (AD) Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Atopic Dermatitis (AD) Report Key Strengths
- Ten Years Forecast
- The United States Coverage
- Atopic Dermatitis (AD) Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Atopic Dermatitis (AD) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- What was the Atopic Dermatitis (AD) market share (%) distribution in 2018 and how it would look like in 2030?
- What would be the Atopic Dermatitis (AD) total market size as well as market size by therapies in the United States during the forecast period (2021–2030)?
- What are the key findings pertaining to the market in the United States?
- At what CAGR, the Atopic Dermatitis (AD) market is expected to grow at the United States level during the forecast period (2021–2030)?
- What would be the Atopic Dermatitis (AD) market outlook in the United States during the forecast period (2021–2030)?
- What would be the Atopic Dermatitis (AD) market growth till 2030 and what will be the resultant market size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What is the disease risk, burden and unmet needs of Atopic Dermatitis (AD)?
- What is the historical Atopic Dermatitis (AD) patient pool in the United States?
- What would be the forecasted patient pool of Atopic Dermatitis (AD) at the United States level?
- What will be the growth opportunities in the United States with respect to the patient population pertaining to Atopic Dermatitis (AD)?
- At what CAGR the population is expected to grow in the United States during the forecast period (2021–2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the treatment of Atopic Dermatitis (AD) along with the approved therapy?
- What are the current treatment guidelines for the treatment of Atopic Dermatitis (AD) in the US?
- What are the Atopic Dermatitis (AD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Atopic Dermatitis (AD)?
- How many therapies are developed by each company for the treatment of Atopic Dermatitis (AD)?
- How many emerging therapies are in the mid-stage and late stage of development for the treatment of Atopic Dermatitis (AD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atopic Dermatitis (AD) therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atopic Dermatitis (AD) and their status?
- What are the key designations that have been granted for the emerging therapies for Atopic Dermatitis (AD)?
- What is the United States historical and forecasted market of Atopic Dermatitis (AD)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Atopic Dermatitis (AD) market
- To understand the future market competition in the Atopic Dermatitis (AD) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis (AD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Atopic Dermatitis (AD) market
- To understand the future market competition in the Atopic Dermatitis (AD) market
1. Key Insights
2. Report Introduction
3. Executive Summary
4. SWOT Analysis
5. Disease Background and Overview
5.1. Signs and Symptoms
5.2. Causes and Triggers
5.3. Clinical presentation
5.5. Skin hypersensitivity – abnormalities of the horny cell layer
5.5.1. Mechanisms involved in inflammation
5.6.1. Serum IgE levels
5.6.2. Peripheral eosinophil count
5.6.3. Serum lactate dehydrogenase level
5.6.4. Serum thymus and activation regulated chemokine level
5.7. Characteristics of eruption
5.7.1. Infancy (younger than 2 years)
5.7.2. Childhood/school-age (2–12 years old)
5.7.3. Adolescence/adulthood (13 years and older)
5.8. Differential diagnosis
5.9. Prevention and Management
5.11. Diagnostic criteria for eczema
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. United States
6.2.1. Assumption and Rationale
6.2.2. Prevalent Population of Atopic Dermatitis (AD) in the United States
6.2.3. Diagnosed Prevalent Population of Atopic Dermatitis (AD) in the United States
6.2.4. Severity-specific distribution of Atopic Dermatitis (AD) in Adults in the United States
6.2.5. Severity-specific distribution of Atopic Dermatitis (AD) in Pediatric Population in the United States
6.2.6. Gender-specific Prevalence of Atopic Dermatitis (AD) in Adults in the United States
7. Recognized Establishments
8.1. Topical treatment
8.1.2. Topical Corticosteroids (TCs)
8.1.3. Topical Calcineurin Inhibitors (TCIs)
8.2. Systemic Treatment
8.2.2. Oral Corticosteroids
8.2.3. Interleukin Inhibitors
8.2.4. JAK inhibitors
8.2.5. PDE4 inhibitor
8.3.1. Bathing Practices
8.3.2. Wet Wrap therapy (WWT)
8.3.3. Stress-Relieving Therapies
9. Atopic Dermatitis (AD) Clinical Guideline: American Academy of Dermatology Association (2014)
9.1. Guidelines for Diagnosis and Assessment
9.1.1. Recommendation for the diagnosis of AD
9.1.2. Recommendations for the use of biomarkers in the assessment of Atopic Dermatitis (AD)
9.1.3. Recommendations for disease severity and clinical outcomes assessment
9.1.4. Recommendations for the assessment of clinical associations of Atopic Dermatitis (AD)
9.2. Guidelines for management and treatment with Topical Therapies
9.2.1. Recommendations for non-pharmacologic interventions for the treatment of AD
9.2.2. Recommendations for the use of topical corticosteroids for the treatment of AD
9.2.3. Recommendations for the use of topical calcineurin inhibitors for the treatment of Atopic Dermatitis (AD)
9.2.4. Recommendations for the use of topical antimicrobials and antiseptics for the treatment of Atopic Dermatitis (AD)
9.2.5. Recommendations for the use of topical antihistamines for the treatment of Atopic Dermatitis (AD)
9.3. Guidelines for Management and Treatment with phototherapy and systemic agents
9.3.1. Recommendations for the use of phototherapy
9.3.2. Recommendations for the use of systemic immunomodulatory agents
9.3.3. Dosing and monitoring guidelines for the use of selected systemic agents
9.3.4. Recommendations for the use of systemic antimicrobials
9.3.5. Recommendations for the use of systemic antihistamines
9.4. Prevention of disease flares and use of adjunctive therapies and approaches
9.4.1. Recommendation for prevention of flares of AD
9.4.2. Recommendations for educational interventions for AD
9.4.3. Recommendations for testing for coexisting allergic disease
9.4.4. Recommendations for other adjunctive and complementary interventions for the treatment of Atopic Dermatitis (AD)
10. Treatment Algorithm
10.1. Treatment Algorithm of AD in Early Childhood
11. Unmet Needs
12. Marketed Products
12.1. Eucrisa (crisaborole): Pfizer
12.1.1. Product Description
12.1.2. Safety and Efficacy
12.2. Dupixent (dupilumab): Regeneron Pharmaceuticals
12.2.1. Product Description
12.2.2. Safety and Efficacy
12.2.3. Current Pipeline Activity
13. Emerging Drugs
13.1. Key Competitors
13.2. Rinvoq (upadacitinib): AbbVie
13.2.1. Product Description
13.2.2. Clinical Development
13.2.3. Safety and Efficacy
13.3. Ly3650150: Eli Lilly and Company
13.3.1. Product Description
13.3.2. Clinical Development
13.3.3. Safety and Efficacy
13.4. Abrocitinib: Pfizer
13.4.1. Product Description
13.4.2. Clinical Development
13.4.3. Safety and Efficacy
13.5. Olumiant (baricitinib) ± TCS: Eli Lilly and Company
13.5.1. Product Description
13.5.2. Current Pipeline Activity
13.5.3. Safety and Efficacy
13.6. Nemolizumab: Galderma
13.6.1. Product Description
13.6.2. Clinical Development
13.6.3. Safety and Efficacy
13.7. Tralokinumab ± Topical Corticosteroids: LEO Pharma
13.7.1. Product Description
13.7.2. Clinical Development
13.7.3. Safety and Efficacy
13.8. Difamilast: Otsuka Pharmaceutical
13.8.1. Product Description
13.8.2. Clinical Development
13.8.3. Safety and Efficacy
13.9. FB825: Oneness Biotech
13.9.1. Product Description
13.9.2. Clinical Development
13.9.3. Safety and Efficacy
14. Market Access and Reimbursement
15. Atopic Dermatitis (AD): The United States Market Analysis
15.1. Key Findings
16. The United States Market Outlook
16.1. Changing market dynamics despite of Dupixent dominance
16.2. United States Market Size
16.2.1. Total Market size of AD
16.2.2. Market Size of Atopic Dermatitis (AD) by Current Therapies
16.2.3. Market Size of Atopic Dermatitis (AD) by Emerging Therapies
17 Market Drivers
18. Market Barriers
19. Case Reports
20.2. Report Methodology
21. DelveInsight Capabilities
23. About DelveInsight
List of Table
Table 1: Summary of Atopic Dermatitis (AD) (AD), Market, Epidemiology, and Key Events (2018–2030)
Table 2: Characteristic features of Atopic Dermatitis (AD) (AD) by age
Table 3: Diagnostic features for eczema
Table 4: Hanifin and Rajka Criteria for Atopic Dermatitis (AD) (AD)
Table 5: Prevalent Population of Atopic Dermatitis (AD) in the United States (2018–2030)
Table 6: Diagnosed Prevalent Population of AD in the United States (2018–2030)
Table 7: Severity-specific distribution of Atopic Dermatitis (AD) in Adults in the United States (2018–2030)
Table 8: Severity-specific distribution of Atopic Dermatitis (AD) in Pediatric Population in the US (2018–2030)
Table 9: Gender-specific Prevalence of Atopic Dermatitis (AD) in Adults in the United States (2018–2030)
Table 10: Recognized Establishments
Table 11: Topical Corticosteroids Ranked by Potency (from Most Potent to Least Potent)
Table 12: Features to be considered in the diagnosis of patients with AD
Table 13: Dosing and monitoring guidelines for the use of selected systemic agents
Table 14: Comparison of emerging drugs under development
Table 15: Dupixent (dupilumab), Clinical Trial Description, 2021
Table 16: Comparison of emerging drugs under development
Table 17: Upadacitinib, Clinical Trial Description, 2021
Table 18: Ly3650150, Clinical Trial Description, 2021
Table 19: PF-04965842, Clinical Trial Description, 2021
Table 20: Baricitinib, Clinical Trial Description, 2021
Table 21: Nemolizumab, Clinical Trial Description, 2021
Table 22: Tralokinumab, Clinical Trial Description, 2021
Table 23: Difamilast, Clinical Trial Description, 2021
Table 24: Ruxolitinib, Clinical Trial Description, 2021
Table 25: DS107, Clinical Trial Description, 2021
Table 26: Delgocitinib, Clinical Trial Description, 2021
Table 27: Bermekimab, Clinical Trial Description, 2021
Table 28: Q301, Clinical Trial Description, 2021
Table 29: Roflumilast, Clinical Trial Description, 2021
Table 30: B244, Clinical Trial Description, 2021
Table 31: Etrasimod, Clinical Trial Description, 2021
Table 32: FB-401, Clinical Trial Description, 2021
Table 33: FB825, Clinical Trial Description, 2021
Table 34: Launch year of emerging therapies in the United States
Table 35: United States Market Size of AD, USD Million (2018–2030)
Table 36: Market size of AD by Current therapies in the US, in USD Million (2018–2030)
Table 37: Market size of AD by emerging therapies in the US, in USD Million (2018–2030)
List of Figures
Figure 1: SWOT Analysis of Atopic Dermatitis (AD)
Figure 2: Prevalent Population of Atopic Dermatitis (AD) in the United States (2018–2030)
Figure 3: Diagnosed Prevalent Population of Atopic Dermatitis (AD) in the United States (2018–2030)
Figure 4: Severity-specific distribution of Atopic Dermatitis (AD) in Adults in the US (2018–2030)
Figure 5: Severity-specific distribution of AD in Pediatric Population in the US (2018–2030)
Figure 6: Gender-specific Prevalence of Atopic Dermatitis (AD) in adults in the United States (2018–2030)
Figure 7: Medical algorithm for the therapeutic management of AD in early childhood, based on the severity
Figure 8: Market Size of Atopic Dermatitis (AD) in the United States, in USD Million (2018–2030)
Figure 9: Market size of AD by Current therapies in the US, in USD Million (2018–2030)
Figure 10: Market size of AD by Emerging therapies in the US, in USD Million (2018–2030)
Eli Lilly and Company